C2CD4C

Across TCGA pan-cancer cohorts, C2CD4C Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C2CD4C data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher C2CD4C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C2CD4C expression acts as an unfavorable survival marker.

COAD and LIHC are the cancer types where C2CD4C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	III,IV	0.035	0.698	<.001	12	view →
LIHC	OS	Median	All	0.217	0.710	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C2CD4C–COAD (DFS)

Open the COAD breakdown →